JP2009502961A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502961A5
JP2009502961A5 JP2008524206A JP2008524206A JP2009502961A5 JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5 JP 2008524206 A JP2008524206 A JP 2008524206A JP 2008524206 A JP2008524206 A JP 2008524206A JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5
Authority
JP
Japan
Prior art keywords
prodrug
deuterium
compound
polymorph
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524206A
Other languages
English (en)
Other versions
JP2009502961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/029461 external-priority patent/WO2007016361A2/en
Publication of JP2009502961A publication Critical patent/JP2009502961A/ja
Publication of JP2009502961A5 publication Critical patent/JP2009502961A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. 式IIの単離された化合物:
    Figure 2009502961
    II
    (式中、X及びXは同時にフルオロであり、又はXは重水素であり、Xは水素若しくは重水素から選択され、各Yは独立して重水素又は水素から選択され、
    前記化合物は以下:
    a)Y
    b)Y
    c)同時にY 8a 及びY 8b 、又は
    d)同時にY 9a 、Y 9b 及びY 9c の1箇所以上が重水素置換されている。)
    又はプロドラッグ、又はそのプロドラッグの塩、又はその水和物、溶媒和物、又は多形体。
  2. 及びXは同時に重水素である、請求項1に記載の化合物又はプロドラッグ、又はそのプロドラッグの塩、又はその水和物、溶媒和物、又は多形体。
  3. 重水素で置換されない水素原子すべては、天然の同位元素の存在度にて存在する、請求項1又は2に記載の化合物。
  4. 有効量の請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体、及び薬学上許容可能なキャリアを含む組成物
  5. 起不全、安定、不安定及び異型の狭心症、高血圧症、肺高血圧症、慢性閉塞性肺疾患、急性呼吸窮迫症候群、悪性高血圧症、褐色細胞腫、鬱血性心不全、急性腎不全、慢性腎不全、アテローム性硬化症、血管の開放性が低下した状態、末梢血管疾患、血管障害、血小板血症、炎症性疾患、心筋梗塞、卒中、気管支炎、慢性喘息、アレルギー性喘息、アレルギー性鼻炎、緑内障、消化性潰瘍、消化管運動性障害、経皮経管冠動脈又は頚動脈血管形成後、バイパス手術後の移植狭窄、骨粗鬆症、早産陣痛、良性の前立腺肥大、及び刺激性腸症候群、男性のヒト及び動物における勃起不全、並びに女性における女性性的興奮障害、卵子との受精を促進するための精子数の減少、インスリン耐性の低下、濾胞の増殖の刺激から選ばれる疾患又は障害に罹っている又はそれに感受性である対象治療に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
  6. 線維症を含む症状の予防又は治療に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
  7. 脊髄損傷を負っている患者における疼痛又は痙縮の緩和に用いられる請求項1に記載の化合物、又はプロドラッグ、又はプロドラッグの塩、又はその水和物、溶媒和物又は多形体を含有する剤。
  8. 起不全の緩和又は予防に用いられる、請求項に記載の
  9. 式XIIIaの化合物
    Figure 2009502961
    XIIIa
    (式中、Dは重水素であり、Yは重水素であり、各水素原子は任意に重水素によって置き換えられる。)。
  10. 重水素で置換されない水素原子すべて及び炭素原子すべては、天然の同位元素の存在度にて存在する、請求項に記載の化合物。
JP2008524206A 2005-07-29 2006-07-28 新規な医薬組成物 Pending JP2009502961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70361205P 2005-07-29 2005-07-29
US70357005P 2005-07-29 2005-07-29
PCT/US2006/029461 WO2007016361A2 (en) 2005-07-29 2006-07-28 Novel pharmaceutical compounds

Publications (2)

Publication Number Publication Date
JP2009502961A JP2009502961A (ja) 2009-01-29
JP2009502961A5 true JP2009502961A5 (ja) 2009-09-10

Family

ID=37709213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524206A Pending JP2009502961A (ja) 2005-07-29 2006-07-28 新規な医薬組成物

Country Status (8)

Country Link
US (1) US20070037815A1 (ja)
EP (2) EP2324886A1 (ja)
JP (1) JP2009502961A (ja)
KR (1) KR20080047375A (ja)
AU (1) AU2006275702A1 (ja)
BR (1) BRPI0615972A2 (ja)
CA (1) CA2616366A1 (ja)
WO (1) WO2007016361A2 (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
MX2009003941A (es) 2006-10-20 2009-04-24 Concert Pharmaceuticals Inc Derivados de 3-(dihidro-1h-pirazolo[4,3-d]pirimidin-5-il)-4-propox ibencenosulfonamida y metodos de uso.
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
AU2008247805A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
US20080319086A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched salmeterol
AU2008299921B2 (en) * 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
WO2009099620A1 (en) * 2008-02-04 2009-08-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
JP2012531433A (ja) * 2009-06-25 2012-12-10 メドリューション リミテッド キナーゼ阻害剤としての置換複素環式化合物とその用法
EP2687854A1 (en) * 2012-07-19 2014-01-22 Chiron AS Test kit for the quantitative determination of narcotic drugs
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
KR20150127249A (ko) 2013-03-13 2015-11-16 보스톤 바이오메디칼, 인크. 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA3194562A1 (en) 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
AU2015399642B2 (en) * 2015-06-26 2020-04-09 Chongqing Dikang Erle Pharma Co. Ltd. Novel phosphodiesterase type-5 inhibitor and application thereof
CN109180580B (zh) 2016-02-28 2021-01-12 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基化合物及包含该化合物的组合物及其用途
JP6969800B2 (ja) 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体
EP3456328A4 (en) 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
WO2019046163A1 (en) 2017-08-28 2019-03-07 Zhihong Chen SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS
WO2019099651A1 (en) * 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Methods of using deuterated pyruvate kinase activators
WO2019168999A1 (en) * 2018-02-28 2019-09-06 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use
BR112021008128A2 (pt) 2018-11-01 2021-08-03 Lynk Pharmaceuticals Co. Ltd. inibidores de janus quinase 1 tricíclicos, e composições e métodos dos mesmos
WO2020146845A1 (en) 2019-01-11 2020-07-16 University Of Rochester Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a
CN117462549A (zh) 2019-02-01 2024-01-30 康威(广州)生物科技有限公司 咪唑并喹啉胺衍生物、及其药物组合物和应用
CN114616234B (zh) 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2021062307A1 (en) * 2019-09-25 2021-04-01 Intra-Cellular Therapies, Inc. Novel methods
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
US20230340491A1 (en) 2020-04-22 2023-10-26 University Of Rochester Compositions and methods for treating metabolic and cardiovascular diseases
CA3224994A1 (en) 2021-06-22 2022-12-29 Dana-Farber Cancer Institute, Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110099A (en) 1975-12-17 1978-08-29 Eli Lilly And Company Novel fluoroalkoxyphenyl-substituted nitrogen heterocycles
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
IT1291320B1 (it) 1997-05-08 1999-01-07 Borregaard Italia Spa Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AU4663100A (en) 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder
KR20060093355A (ko) 1999-08-03 2006-08-24 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US7737147B2 (en) 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6892568B2 (en) 2003-02-03 2005-05-17 Honda Giken Kogyo Kabushiki Kaisha Noise detection system and method
ATE341327T1 (de) 2001-02-28 2006-10-15 Merck & Co Inc Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
MXPA03007785A (es) 2001-02-28 2003-12-08 Merck & Co Inc Derivados de piperidina acilados como agonistas del receptor de melanocortina 4.
KR20030081520A (ko) 2001-03-14 2003-10-17 오노 야꾸힝 고교 가부시키가이샤 Ep1 안타고니스트를 유효 성분으로서 함유하는 울병의치료제
CA2441792C (en) * 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
LV12979B (en) 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP1461022A2 (en) 2001-12-17 2004-09-29 ALTANA Pharma AG Use of selective pde5 inhibitors for treating partial and global respiratory failure
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030235609A1 (en) 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US7091207B2 (en) 2002-05-22 2006-08-15 Virginia Commonwealth University Method of treating myocardial infarction with PDE-5 inhibitors
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
US20040132731A1 (en) 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20050070969A1 (en) 2002-09-06 2005-03-31 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation and the delivery of drugs to the sacral and pudendal nerves
US7369894B2 (en) 2002-09-06 2008-05-06 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US20040180958A1 (en) 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
GB0230025D0 (en) 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
WO2004069167A2 (en) 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
JP4533590B2 (ja) 2003-02-28 2010-09-01 ファイザー株式会社 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
AR043434A1 (es) 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
BRPI0411347A (pt) 2003-06-10 2006-07-11 Pfizer combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
JP2007517049A (ja) 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法

Similar Documents

Publication Publication Date Title
JP2009502961A5 (ja)
JP7169412B2 (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
AU2018236691B2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2009502963A5 (ja)
JP6345645B2 (ja) 横隔膜機能を向上させるための方法
JP2010533203A5 (ja)
JP4477097B2 (ja) 中枢神経系障害の治療のための(2s)−(4e)−n−メチル−5−[3−(5−イソプロポキシピリジン)イル]−4−ペンテン−2−アミンの多形形態
US20090181968A1 (en) Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides
TW201305169A (zh) 7-環戊基-2-(5-哌□-1-基-吡啶-2-基胺基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲醯胺之鹽類及其製備方法
RU2008100933A (ru) ПИРРОЛО[2,3-b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
JP2017522276A5 (ja)
JP2008510762A5 (ja)
JP2013529647A5 (ja)
JP2013532162A5 (ja) 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および/または予防のためのその使用
TW201004941A (en) Alpha7 nicotinic acetylcholine receptor inhibitors
TW200900068A (en) Novel N,N'-2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors
JP2022166179A (ja) アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
JP2007051155A (ja) ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体
JP5710490B2 (ja) (r)−5−((e)−2−(ピロリジン−3−イルビニル)ピリミジンの合成および新規の塩形態
JP2007523206A (ja) Cb2受容体モジュレーターとしてのピリジン誘導体およびその使用
RU2004133811A (ru) Новые соединения
JP2019508385A (ja) テネリグリプチンのシュウ酸塩およびその溶媒和物、中間体、その調製方法およびマーカー
JP2007507464A (ja) 新規のアミノピリジン誘導体
CN114206836B (zh) 新型吡咯化合物
JPWO2019220390A5 (ja)